The duration of life in cirrhosis with portal hypertension and splenomegaly depends on the outcome of subsequent treatment. This is the decompensated phase, and if treated aggressively, the patient’s life expectancy can be effectively extended to several decades.
In the decompensated phase of cirrhosis, there are symptoms such as hepatic decompensation and portal hypertension, which includes splenomegaly, collateral circulation formation and ascites. Patients in the compensated phase are able to slow down the liver function impairment and reverse the lesions through active treatment. In the decompensated stage, the focus is on preserving liver function and treating the complications, as well as using liver transplantation to sustain life.
Therefore, by relieving the symptoms of portal hypertension and other complications, liver function can be preserved and life expectancy can be prolonged. Portal hypertension is usually treated with a transjugular intrahepatic portosystemic shunt, hemostatic drugs such as growth inhibitors and octreotide, or endoscopic treatment of upper gastrointestinal bleeding. Hepatic encephalopathy is treated with L-ornithine as well as lactulose and neomycin.
Severe cases of impaired liver function in which the patient’s life is in danger can be treated with liver transplantation so that the patient’s life expectancy can be similar to that of a normal person.
Therefore, how long one can live with portal hypertension and splenomegaly after cirrhosis depends on the aggressiveness and effectiveness of the subsequent treatment. If liver function can be improved through active treatment, then the patient’s life expectancy can be effectively prolonged. Therefore, it is necessary to carry out treatment under the guidance of doctors and not to be discouraged.